Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.18B |
| Revenue (ttm) | 720.13M +98.0% |
| Net Income | -228.03M |
| EPS | -3.76 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 46.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 206.00 |
| Previous Close | 204.00 |
| Day's Range | 206.00 - 206.00 |
| 52-Week Range | 137.00 - 210.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial StatementsNews
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, ...
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
Oppenheimer raised the firm’s price target on Ascendis Pharma to $312 from $304 and keeps an Outperform rating on the shares. The firm has revised its Ascendis (ASND) model to…
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Ascendis Pharma (ASND) to $273 from $275 and keeps an Overweight rating on the shares after the company and…
H.C. Wainwright trims Ascendis target, says litigation overhang removed
H.C. Wainwright lowered the firm’s price target on Ascendis Pharma (ASND) to $344 from $345 and keeps a Buy rating on the shares. The Yuviwel royalty settlement with BioMarin (BMRN)…
BioMarin price target raised to $60 from $59 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $59 and keeps a Neutral rating on the shares after Ascendis Pharma (ASND) agreed to pay the…
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
Ascendis Pharma rises 8.0%
Ascendis Pharma (ASND) is up 8.0%, or $19.81 to $267.72.
Ascendis Pharma price target lowered to $304 from $306 at BofA
BofA lowered the firm’s price target on Ascendis Pharma (ASND) to $304 from $306 and keeps a Buy rating on the shares after the company a binding term sheet with…
Ascendis Pharma price target lowered to $330 from $333 at Jefferies
Jefferies lowered the firm’s price target on Ascendis Pharma (ASND) to $330 from $333 and keeps a Buy rating on the shares after the company settled its dispute with BioMarin…
Ascendis Pharma price target lowered to $326 from $328 at Stifel
Stifel lowered the firm’s price target on Ascendis Pharma (ASND) to $326 from $328 and keeps a Buy rating on the shares after the company settled its dispute with BioMarin…
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with Bi...
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
BioMarin (BMRN) announced that it has entered into binding terms with Ascendis Pharma (ASND), resolving the patent and ancillary disputes pending globally, including before the U.S. International Trad...
Ascendis Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $345 price target The firm believes the shares at current levels are underpricing the Yuviwel launch. The…
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasi...
BMO starts Ascendis at Outperform on further platform growth
BMO Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $319 price target The firm says Ascendis has delivered three FDA approvals with its proprietary TransCon platform...
Ascendis Pharma initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $319 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injecti...
Ascendis Pharma reports Q2 EPS 90c, consensus 77c
Reports Q2 revenue $339.29M, consensus $329.9M. “Our patient focus has driven achievement of important milestones and strong demand for our TransCon products as Ascendis continues to transform into a ...
Ascendis Pharma price target lowered to $329 from $345 at Barclays
Barclays lowered the firm’s price target on Ascendis Pharma (ASND) to $329 from $345 and keeps an Overweight rating on the shares. The firm updated the company’s model for its…
Ascendis Pharma Earnings Call Transcript: Q2 2026
Q2 2026 saw product revenue more than double year-over-year, driven by strong demand for YORVIPATH, SKYTROFA, and the launch of UBEGLA. The company remains on track for its Vision 2030 revenue goals, with robust global uptake, high patient retention, and ongoing pipeline expansion.
Ascendis Pharma Earnings release: Q2 2026
Ascendis Pharma released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Ascendis Pharma Reports Second Quarter 2026 Financial Results
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thur...
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.
Ascendis Pharma Slides: Study update presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.